random cc notes | CYDY Message Board Posts
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left) 5-yrs @ $199 (only 30 left) 2-yrs @ $99 (only 27 left)

CYDY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  5680 of 5789  at  9/16/2020 8:08:56 PM  by

gg100


random cc notes

 m/m trial: 10 patients had score of zero, 30 patients were 4 or less
 
Seethamraju patients were extremely sick. 
 
Agresti 4 patient results very impressive. critically ill, so much so that family was encouraged to say goodbye. all four patients received multiple other treatments and did not improve until given leronlimab.
 
Recknor: some of his patients were four weeks infected when they were dosed with leronlimab. He thinks leronlimab is indicated for mild/moderate who are long infected but who have not improved.
 
FDA EUA and MHRA fast track: both agencies want to see CD12 results. phase 3 will be needed for mild/moderate.
 
must provide MHRA with EIND details  
 
DODy: update MHRA for covid, discuss covid reg path in UK. shared m/m results. MHRA recs early access meds, access prior to full authorization. the submission process has been initiated.
 
NP: phase 3 for moderate population, four weekly injections. sites ready to initiate. 
 
kelly: longhaulers. some tipping point data??? blood brain barrier LL crosses in macaques. 70% receptor occupancy.
 
Recknor: new VP Clinical Development. cognitive fog in moderate patients who had symptoms for four weeks. "Marked" changes in cognitve on these patients. "Maybe this is post-viral".
 
NP: fastest path to covid approval is CD12 plus moderate plus long haulers 
 
Dody: complete agreement with FDA as to what information needs to be provided for HIV BLA 
 
Kelly NASH: approval for phase 2. mid to late november first patient injection and we will announce that patient injection when it happens.
 
Pourhassan: Immunomedics 21 billion acquisition. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 9     Views: 191
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
5684 Re: random cc notes eagle76 2 9/17/2020 10:21:23 AM






Financial Market Data provided by
.


Loading...